StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where DVA sits in our scored universe today on a single observational measurement. P85 means DVA ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $200.83 | $198.93 | -0.95% | 1.1M |
| 05-12 | $197.50 | $200.54 | +1.54% | 1.4M |
| 05-13 | $201.10 | $198.10 | -1.49% | 0.6M |
| 05-14 | $197.12 | $192.58 | -2.30% | 0.9M |
| 05-15 | $193.67 | $199.74 | +3.13% | 0.7M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2020 2020-12-31 | Annual 2019 2019-12-31 | Q3 2019 2019-09-30 | Q2 2019 2019-06-30 |
|---|---|---|---|---|
Revenue | $11.04B | $10.92B | $8.15B | $5.37B |
Operating Income | $1.69B | $1.64B | $378.34M | $461.89M |
Net Income | $773.64M | $810.98M | $143.27M | $273.55M |
EPS (Diluted) | $6.31 | $5.27 | $0.95 | $1.64 |
Total Assets | $16.99B | $17.31B | $17.45B | $19.93B |
Total Liabilities | $14.09B | $13.81B | $13.64B | $14.50B |
Cash & Equivalents | $324.96M | $1.10B | $1.25B | $3.58B |
Free Cash Flow OCF − CapEx | $1.30B | $1.31B | $844.64M | $377.20M |
Shares Outstanding | 109.93M | 125.84M | 133.89M | 164.47M |
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.